Anthem Biosciences posts Q1 FY26 PAT at Rs. 135.8 Cr

The CRDMO segment contributed Rs. 452.7 crore, recording a robust 70.5 per cent YoY increase

Cohance Lifesciences reports 13% revenue growth in Q1 FY26

During the quarter, construction began on a US$ 10 million bioconjugation cGMP suite at NJ Bio’s Princeton site

Marksans Pharma reports Q1 FY26 gross profit 8.9% higher at Rs. 358.2 Cr

EBITDA stood at Rs. 100.1 crore with a margin of 16.1 per cent

Indoco Remedies receives final USFDA approval for rivaroxaban tablets

Rivaroxaban is used to treat venous thromboembolism

Apollo Hospitals Q1 FY26 PAT up 42% to Rs. 433 Cr

Apollo has also announced plans to add over 4,300 beds in the next five years with an investment of over Rs. 7,600 crore

Granules India Q1 FY26 PAT slips to Rs. 112.6 Cr

Zydus Lifesciences reports Q1 FY26 net profit at Rs. 1,466.8 Cr

The company reported revenue from operations at Rs. 6,573.7 crore, up 6 per cent YoY

Pfizer launches 20-valent Pneumococcal Conjugate Vaccine for adults in India

Pfizer's vaccine helps protect against clinically relevant 20 serotypes responsible for a majority of invasive and non-invasive pneumococcal disease

Briefs: Nectar Lifesciences, Cipla and Marksans Pharma

Marksans Pharma gets USFDA nod for acid reflux drug

Zydus receives final approval from USFDA for Diltiazem Hydrochloride Tablets USP

Diltiazem works by relaxing blood vessels, which reduces the workload on the heart and increases blood and oxygen supply to the heart muscle